Zhang Y, Springfield R, Chen S, Li X, Feng X, Moshirian R
Front Immunol. 2019; 10:1126.
PMID: 31244823
PMC: 6562299.
DOI: 10.3389/fimmu.2019.01126.
Krijgsman D, Hokland M, Kuppen P
Front Immunol. 2018; 9:367.
PMID: 29535734
PMC: 5835336.
DOI: 10.3389/fimmu.2018.00367.
Kohlgruber A, Donado C, LaMarche N, Brenner M, Brennan P
Immunogenetics. 2016; 68(8):649-63.
PMID: 27457886
PMC: 5745583.
DOI: 10.1007/s00251-016-0944-8.
Felley L, Gumperz J
Immunogenetics. 2016; 68(8):611-22.
PMID: 27393663
PMC: 9238296.
DOI: 10.1007/s00251-016-0936-8.
Subrahmanyam P, Carey G, Webb T
J Immunol. 2014; 193(5):2096-105.
PMID: 25070854
PMC: 4169674.
DOI: 10.4049/jimmunol.1400155.
Boosting the Immune Response: The Use of iNKT cell ligands as vaccine adjuvants.
Subrahmanyam P, Webb T
Front Biol (Beijing). 2012; 7(5):436-444.
PMID: 23264781
PMC: 3524977.
DOI: 10.1007/s11515-012-1194-2.
Characterization of human invariant natural killer T cells expressing FoxP3.
Engelmann P, Farkas K, Kis J, Richman G, Zhang Z, Liew C
Int Immunol. 2011; 23(8):473-84.
PMID: 21708895
PMC: 8139402.
DOI: 10.1093/intimm/dxr040.
Natural killer T cells are not the predominant T cell in asthma and likely modulate, not cause, asthma.
Thomas S, Chyung Y, Luster A
J Allergy Clin Immunol. 2010; 125(5):980-4.
PMID: 20304475
PMC: 2866827.
DOI: 10.1016/j.jaci.2010.01.032.
Adoptive immunotherapy mediated by ex vivo expanded natural killer T cells against CD1d-expressing lymphoid neoplasms.
Bagnara D, Ibatici A, Corselli M, Sessarego N, Tenca C, De Santanna A
Haematologica. 2009; 94(7):967-74.
PMID: 19454494
PMC: 2704307.
DOI: 10.3324/haematol.2008.001339.
NKT cells at the maternal-fetal interface.
Boyson J, Aktan I, Barkhuff D, Chant A
Immunol Invest. 2008; 37(5):565-82.
PMID: 18716938
PMC: 2831232.
DOI: 10.1080/08820130802191409.
Human natural killer T cells are heterogeneous in their capacity to reprogram their effector functions.
Eger K, Sundrud M, Motsinger A, Tseng M, Van Kaer L, Unutmaz D
PLoS One. 2006; 1:e50.
PMID: 17183680
PMC: 1762372.
DOI: 10.1371/journal.pone.0000050.
A structural basis for selection and cross-species reactivity of the semi-invariant NKT cell receptor in CD1d/glycolipid recognition.
Kjer-Nielsen L, Borg N, Pellicci D, Beddoe T, Kostenko L, Clements C
J Exp Med. 2006; 203(3):661-73.
PMID: 16505140
PMC: 2118261.
DOI: 10.1084/jem.20051777.
The innate immune system and HIV pathogenesis.
Eger K, Unutmaz D
Curr HIV/AIDS Rep. 2005; 2(1):10-5.
PMID: 16091243
DOI: 10.1007/s11904-996-0003-4.
CD56+-T-cell responses to bacterial superantigens and immune recognition of attenuated vaccines.
Saikh K, Dyas B, Kissner T, Ulrich R
Clin Diagn Lab Immunol. 2003; 10(6):1065-73.
PMID: 14607868
PMC: 262457.
DOI: 10.1128/cdli.10.6.1065-1073.2003.
Intracellular pathways of CD1 antigen presentation.
Moody D, Porcelli S
Nat Rev Immunol. 2003; 3(1):11-22.
PMID: 12511872
DOI: 10.1038/nri979.
CD1d and invariant NKT cells at the human maternal-fetal interface.
Boyson J, Rybalov B, Koopman L, Exley M, Balk S, Racke F
Proc Natl Acad Sci U S A. 2002; 99(21):13741-6.
PMID: 12368486
PMC: 129762.
DOI: 10.1073/pnas.162491699.
CD1d-restricted human natural killer T cells are highly susceptible to human immunodeficiency virus 1 infection.
Motsinger A, Haas D, Stanic A, Van Kaer L, Joyce S, Unutmaz D
J Exp Med. 2002; 195(7):869-79.
PMID: 11927631
PMC: 2193731.
DOI: 10.1084/jem.20011712.
Functionally distinct subsets of CD1d-restricted natural killer T cells revealed by CD1d tetramer staining.
Gumperz J, Miyake S, Yamamura T, Brenner M
J Exp Med. 2002; 195(5):625-36.
PMID: 11877485
PMC: 2193772.
DOI: 10.1084/jem.20011786.
Glycolipid targets of CD1-mediated T-cell responses.
Moody D, Besra G
Immunology. 2001; 104(3):243-51.
PMID: 11722638
PMC: 1783304.
DOI: 10.1046/j.1365-2567.2001.01326.x.
CD4-CD8- T cells bearing invariant Valpha24JalphaQ TCR alpha-chain are decreased in patients with atopic diseases.
Oishi Y, Sakamoto A, Kurasawa K, Nakajima H, Nakao A, Nakagawa N
Clin Exp Immunol. 2000; 119(3):404-11.
PMID: 10691910
PMC: 1905593.
DOI: 10.1046/j.1365-2249.2000.01157.x.